Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20204100 | 0.81 | SSTR4 (0.38) | CA14SSTR4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20173462 | 0.76 | PDE1A (0.34) | HDAC6 | |
| SCHEMBL503444 | 0.76 | CA14 (0.53) | CA14SSTR4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20173477 | 0.76 | SSTR4 (0.30) | SSTR4 | |
| SCHEMBL15668049 | 0.75 | SSTR4 (0.41) | CA14SSTR4HDAC6 | |
| SCHEMBL20173488 | 0.75 | — | — | |
| SCHEMBL745378 | 0.74 | CA14 (0.51) | CA14SSTR4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL28584989 | 0.74 | CA14 (0.51) | CA14SSTR4CHRNB2CHRNB4CHRNA3 | |
| Alcohol SCHEMBL17363353 | 0.73 | SSTR4 (0.40) | CA14SSTR4HDAC6 | |
| SCHEMBL7936929 | 0.73 | CA14 (0.42) | CA14SSTR4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | CA14 2780/4885SSTR4 2377/4885CHRNB2 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.